Skip to main content
Teaser
Kapseln
Teaser
Teaser

Chitosan HCl

Chitosan for vaccine development against SARS-CoV-2

The global spread of SARS-CoV-2 can only be contained through vaccine development. Vector vaccines (DNA and viral) can be produced rapidly and inexpensively with current synthesis technologies. Challenges with DNA vaccines include degradation by DNases, inefficient uptake by antigen-presenting cells, and low immunogenicity. The Quil-A-loaded chitosan particulate adjuvant system (QAC) enables transport of plasmid DNA directly to target cells and delayed release over time. Here, we present two recent studies about chitosan-based delivery systems for vaccines.

Modification of denture materials with chitosan salts

Fungal infection with Candida of dentures is a common complication. The adhesion of microorganisms such as Candida is influenced by material properties such as surface charge, hydrophobicity and roughness. The formation of oral biofilms is associated with caries, periodontitis or denture stomatitis. It is therefore important to prevent the formation of biofilms, also because antifungal agents are of little help.
The polymer polymethyl methacrylate (PMMA) is widely used for denture fabrication due to its biocompatibility, but it is susceptible to biofilm formation. Therefore, research into strategies to endow dentures with antifungal properties is important.

Chitosan as adjuvant for vaccines

Adjuvants in vaccines are potent enhancers, which ensure that even small amounts of pathogens induce a permanent immune response. They are particularly necessary for inactivated vaccines and vaccines with antigen subunits. Several studies investigated chitosan as an adjuvant or antigen delivery system in various formulations (gels, aqueous dispersion, micro- and nanoparticles).

We have expand our chitosan chloride product range

Due to increased requests we expanded our wide product range one more time. Henceforth you can order different chitosan HCL from HMC not only in customer manufacturing, now we also provide chitosan chloride in various standard specifications with different degrees of deacetylation and viscosity-ranges. Now you can specific compare chitosan-chlorides in your research as well as generate precise properties in your pharmaceutical products.

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.